BCM
BML Capital Management Portfolio holdings
AUM
$131M
This Quarter Return
+22.99%
1 Year Return
+89.45%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$111M
AUM Growth
+$111M
(-3.9%)
Cap. Flow
-$22M
Cap. Flow
% of AUM
-19.76%
Top 10 Holdings %
Top 10 Hldgs %
79.87%
Holding
38
New
7
Increased
5
Reduced
8
Closed
7
Top Buys
| 1 |
Atea Pharmaceuticals
AVIR
|
$8.36M |
| 2 |
iShares 0-3 Month Treasury Bond ETF
SGOV
|
$5.53M |
| 3 |
Quince Therapeutics
QNCX
|
$2.12M |
| 4 |
Passage Bio
PASG
|
$1.62M |
| 5 |
CalciMedica
CALC
|
$356K |
Top Sells
| 1 |
Tilly's
TLYS
|
$6.76M |
| 2 |
Abercrombie & Fitch
ANF
|
$6.72M |
| 3 |
STSA
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
|
$4.5M |
| 4 |
Disc Medicine
IRON
|
$4.41M |
| 5 |
EMBK
Embark Technology, Inc. Common Stock
EMBK
|
$3.61M |
Sector Composition
| 1 | Healthcare | 59.2% |
| 2 | Consumer Discretionary | 5.18% |
| 3 | Technology | 2.81% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
$42.1B
| $18.4M | 16.52% | 200,000 | – | – |
|
|
2
iShares 0-3 Month Treasury Bond ETF
SGOV
$56.1B
| $18.1M | 16.29% | 180,000 +55,000 | +44% | +$5.53M |
|
|
CYT
3
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
| $8.45M | 7.6% | 3,250,000 +103,704 | +3% | +$270K |
|
|
4
Atea Pharmaceuticals
AVIR
$267M
| $8.36M | 7.52% | +2,236,239 | New | +$8.36M |
|
5
Adverum Biotechnologies
ADVM
$64.6M
| $8.2M | 7.38% | 5,157,179 -1,910,000 | -27% | -$3.04M |
|
|
PRDS
6
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
| $6.86M | 6.17% | 3,791,633 -194,944 | -5% | -$353K |
|
7
Tourmaline Bio
TRML
$601M
| $6.08M | 5.47% | 2,000,000 +70,516 | +4% | +$214K |
|
8
Athira Pharma
ATHA
$15.3M
| $5.5M | 4.95% | 1,864,907 | – | – |
|
|
CLYM
9
Climb Bio, Inc. Common Stock
CLYM
$151M
| $4.43M | 3.99% | 1,583,170 -75,000 | -5% | -$210K |
|
|
10
Abercrombie & Fitch
ANF
$4.46B
| $4.43M | 3.98% | 117,500 -178,278 | -60% | -$6.72M |
|
11
Astrotech Corp
ASTC
$8.72M
| $3.12M | 2.81% | 220,410 | – | – |
|
12
Oramed Pharmaceuticals
ORMP
$90.2M
| $3.04M | 2.74% | 850,000 -505,925 | -37% | -$1.81M |
|
|
13
Quince Therapeutics
QNCX
$85.9M
| $2.12M | 1.91% | +1,411,839 | New | +$2.12M |
|
|
14
Passage Bio
PASG
$22.7M
| $1.94M | 1.74% | 2,058,767 +1,721,300 | +510% | +$1.62M |
|
15
Forte Biosciences
FBRX
$137M
| $1.8M | 1.62% | 1,735,075 | – | – |
|
16
Enliven Therapeutics
ELVN
$1.2B
| $1.52M | 1.36% | 74,232 -137,947 | -65% | -$2.82M |
|
|
ORKA
17
Oruka Therapeutics, Inc. Common Stock
ORKA
$554M
| $1.44M | 1.29% | 706,930 | – | – |
|
|
18
Tilly's
TLYS
$59.4M
| $1.34M | 1.2% | 190,518 -964,326 | -84% | -$6.76M |
|
19
Lisata Therapeutics
LSTA
$19.9M
| $902K | 0.81% | 243,839 | – | – |
|
20
Verrica Pharmaceuticals
VRCA
$52.8M
| $866K | 0.78% | 150,000 | – | – |
|
21
Surrozen
SRZN
$104M
| $802K | 0.72% | 1,459,084 -34,953 | -2% | -$19.2K |
|
22
Milestone Pharmaceuticals
MIST
$156M
| $777K | 0.7% | 272,500 +52,500 | +24% | +$150K |
|
23
Retractable Technologies
RVP
$25.1M
| $769K | 0.69% | 668,575 | – | – |
|
24
NextCure
NXTC
$13.5M
| $552K | 0.5% | 306,465 | – | – |
|
|
LENZ
25
LENZ Therapeutics
LENZ
$1.1B
| $396K | 0.36% | 152,291 | – | – |
|